Drug-resistant tuberculosis treatment

DOT 
directly observed treatment
DR-TB 
drug-resistant tuberculosis
DST 
drug susceptibility testing
ECG 
electrocardiogram
EDRWeb 
Electronic Drug-Resistant Tuberculosis Register (South
Africa)
FDC 
fixed-dose combination (medicines)
GDF 
Global Drug Facility
GDG 
Guideline Development Group
GRADE 
Grading of Recommendations Assessment, Development and Evaluation
HIV 
human immunodeficiency virus
HR 
isoniazid–rifampicin
HREZ 
isoniazid–rifampicin–ethambutol–pyrazinamide
(H)REZ 
(isoniazid optional)–rifampicin–ethambutol–pyrazinamide
Hr-TB 
rifampicin-susceptible, isoniazid-resistant tuberculosis
IPD 
individual patient data (or
dataset)
IPD-MA 
individual patient data meta-analysis
IQR 
interquartile range
LPA 
line probe assay
LTBI 
latent tuberculosis infection

---

WHO consolidated 
guidelines 
on
tuberculosis: 
drug-resistant tuberculosis treatment
viii
MDR-TB 
multidrug-resistant tuberculosis
MDR/RR-TB 
multidrug- or rifampicin-resistant tuberculosis
MIC 
minimum inhibitory concentration
MSF 
Médecins Sans Frontières
NTP 
national TB control programme
PICO 
population, intervention, comparator and outcomes
PLHIV 
people living with HIV
QD 
once a day
QTcF 
corrected QT interval by Fredericia
RCT 
randomized controlled trial
REZ 
rifampicin–ethambutol–pyrazinamide
RR-TB 
rifampicin-resistant TB